NASDAQ:FBIO

Fortress Biotech - FBIO Stock Forecast, Price & News

$0.72

-0.01 (-1.36%)

(As of 11/25/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.71
▼
$0.76
50-Day Range: $0.68
▼
$0.98
52-Week Range: $0.67
▼
$2.98

Volume: 28,943 shs
Average Volume: 127,249 shs
Market Capitalization: $78.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

Fortress Biotech MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,210.3% Upside
$9.50 Price Target
Short Interest: Healthy
0.77% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$69,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.82) to ($0.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

145th out of 1,044 stocks

Pharmaceutical Preparations Industry

66th out of 510 stocks

3.5

Analyst's Opinion

Consensus Rating
Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, Fortress Biotech has a forecasted upside of 1,210.3% from its current price of $0.73.
Amount of Analyst Coverage
Fortress Biotech has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.77% of the float of Fortress Biotech has been sold short.
Short Interest Ratio / Days to Cover
Fortress Biotech has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fortress Biotech has recently increased by 2.33%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Fortress Biotech does not currently pay a dividend.
Dividend Growth
Fortress Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FBIO.

2.8

News and Social Media Coverage

News Sentiment
Fortress Biotech has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Fortress Biotech this week, compared to 1 article on an average week.
Search Interest
9 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fortress Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $69,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
26.30% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 28.66% of the stock of Fortress Biotech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Fortress Biotech are expected to grow in the coming year, from ($0.82) to ($0.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fortress Biotech is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fortress Biotech is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Fortress Biotech has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fortress Biotech (NASDAQ:FBIO) Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Stock News Headlines

November 20, 2022 | americanbankingnews.com

FY2022 EPS Estimates for Fortress Biotech, Inc. (NASDAQ:FBIO) Lifted by Cantor Fitzgerald

November 15, 2022 | finance.yahoo.com

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

November 15, 2022 | finance.yahoo.com

Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates

November 8, 2022 | finance.yahoo.com

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

October 27, 2022 | finance.yahoo.com

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

October 26, 2022 | finance.yahoo.com

Insider Buying: The Fortress Biotech, Inc. (NASDAQ:FBIO) Executive Chairman Just Bought US$70k Worth Of Shares

October 7, 2022 | seekingalpha.com

Fortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 declares $0.1953 dividend

October 6, 2022 | markets.businessinsider.com

EQS-News: Fortress Bios Portfolio Of Marketed Drugs Could Soon See Three Additions

October 6, 2022 | finance.yahoo.com

Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

October 5, 2022 | benzinga.com

Fortress Bio's Portfolio Of Marketed Drugs Could Soon See Three Additions

October 5, 2022 | finance.yahoo.com

Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

September 8, 2022 | msn.com

Fortress Biotech Earnings Perspective: Return On Capital Employed

September 8, 2022 | finance.yahoo.com

Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

August 22, 2022 | nasdaq.com

Fortress Biotech Series A Cumulative Redeemable Perpetual Preferred Stock Shares Cross 11.5% Yield Mark

August 12, 2022 | finance.yahoo.com

Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 11, 2022 | finance.yahoo.com

Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates

August 11, 2022 | finance.yahoo.com

Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

August 11, 2022 | finance.yahoo.com

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 11, 2022 | finance.yahoo.com

Fortress Biotech Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 9, 2022 | finance.yahoo.com

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

August 3, 2022 | finance.yahoo.com

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

July 27, 2022 | finance.yahoo.com

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

July 23, 2022 | finance.yahoo.com

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shift From Loss To Profit

July 22, 2022 | finance.yahoo.com

Fortress Biotech Appoints David Jin as Chief Financial Officer

July 14, 2022 | benzinga.com

B. Riley Securities Maintains Buy Rating for Fortress Biotech: Here's What You Need To Know

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

FBIO Company Calendar

Last Earnings: 11/15/2021
Today: 11/27/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/27/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:FBIO
CUSIP: 21976U10
CIK: 1429260
Web: www.fortressbiotech.com
Phone: (781) 652-4500
Fax: 781-652-4545
Employees: 173
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.50
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +1,210.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-64,700,000.00
Net Margins: -117.49%
Pretax Margin: -289.25%
Return on Equity: -54.56%
Return on Assets: -24.45%

Debt

Debt-to-Equity Ratio: 0.91
Current Ratio: 2.43
Quick Ratio: 2.28

Sales & Book Value

Annual Sales: $68.79 million
Price / Sales: 1.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.94 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: 107,740,000
Free Float: 79,401,000
Market Cap: $78.11 million
Optionable: Optionable
Beta: 1.92

Key Executives

Dr. Lindsay Allan Rosenwald (Age 67)
Exec. Chairman, Pres & CEO
Comp: $92.65k

Mr. Michael S. Weiss Esq. (Age 56)
Vice Chairman & Exec. Vice Chairman of Strategic Devel.
Comp: $92.65k

Dr. George C. Avgerinos (Age 68)
Sr. VP of Biologics Operations
Comp: $524.35k

Ms. Robyn M. Hunter (Age 60)
Exec. Officer
Comp: $555.31k

Mr. David Jin
CFO & Head of Corp. Devel.

Mr. Samuel Berry
Gen. Counsel & Corp. Sec.

Dr. Thomas F. Schaible
Project Leader of Inflammatory Bowel Disease

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

FBIO Stock - Frequently Asked Questions

Should I buy or sell Fortress Biotech stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares.
View FBIO analyst ratings or view top-rated stocks.
What is Fortress Biotech's stock price forecast for 2023?: 5 Wall Street analysts have issued 1 year price targets for Fortress Biotech's shares. Their FBIO share price forecasts range from $6.00 to $20.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 1,210.3% from the stock's current price.
View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts.
How have FBIO shares performed in 2022?: Fortress Biotech's stock was trading at $2.50 at the beginning of the year. Since then, FBIO shares have decreased by 71.0% and is now trading at $0.7250.
View the best growth stocks for 2022 here.
When is Fortress Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our FBIO earnings forecast.
How were Fortress Biotech's earnings last quarter?: Fortress Biotech, Inc. (NASDAQ:FBIO) announced its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.06. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to the consensus estimate of $18.41 million. Fortress Biotech had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 54.56%.
What other stocks do shareholders of Fortress Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX).

What is Fortress Biotech's stock symbol?: Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
Who are Fortress Biotech's major shareholders?: Fortress Biotech's stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.67%), Vanguard Group Inc. (4.74%), Tang Capital Management LLC (3.89%), Shikiar Asset Management Inc. (0.78%), Perkins Capital Management Inc. (0.74%) and Renaissance Technologies LLC (0.41%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter.
View institutional ownership trends.
How do I buy shares of Fortress Biotech?: Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fortress Biotech's stock price today?: One share of FBIO stock can currently be purchased for approximately $0.73.
How much money does Fortress Biotech make?: Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $78.11 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.
How many employees does Fortress Biotech have?: The company employs 173 workers across the globe.
How can I contact Fortress Biotech?: Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545.

This page (NASDAQ:FBIO) was last updated on 11/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fortress Biotech - FBIO Stock Forecast, Price & News

Fortress Biotech MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Fortress Biotech (NASDAQ:FBIO) Stock

FBIO Stock News Headlines

FBIO Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

FBIO Stock - Frequently Asked Questions

Overall MarketRank^™